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Abstract Colorectal carcinogenesis is a process that
follows a stepwise cascade that goes from the normal to an
invisible pretumor stage ultimately leading to grossly vis-
ible tumor progression. During pretumor progression, an
increasing accumulation of genetic alterations occurs, by
definition without visible manifestations. It is generally
thought that stem cells in the crypt base are responsible for
this initiation of colorectal cancer progression because they
are the origin of the differentiated epithelial cells that
occupy the crypt. Furthermore, they are characterized by a
long life span that enables them to acquire these cumula-
tive mutations. Recent studies visualized the dynamics of
stem cells both in vitro and in vivo. Translating this work
into clinical applications will contribute to the evaluation
of patients’ predisposition for colorectal carcinogenesis
and may help in the design of preventive measures for
high-risk groups. In this review, we outline the progress
made in the research into tracing stem cell dynamics.
Further, we highlight the importance and potential clinical
value of tracing stem cell dynamics in pretumor
progression.
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Introduction
Colorectal cancer (CRC) is the third commonest cancer
worldwide. In 2012, CRC was diagnosed in more than one
million patients, accounting for 9.7 % of all cancers, with
subsequently high global cancer mortality [1]. CRC death
can be prevented by early detection of carcinomas in a
curable stage, by removal of the precursor lesions, or by
preventive measures in patients with well-established and
well-defined risk factors. The appearance of adenomatous
polyps is generally the first visible feature of CRC
tumorigenesis, and removal of these polyps is in that case
one of the first priorities. However, approximately
12–40 % of the adenomas appear to be flat or depressed,
and they may be missed during endoscopic visualization
[2]. This will hamper early detection and proper secondary
prevention of CRC. Therefore, optimal measures of pri-
mary and secondary prevention require a thorough under-
standing of the pathogenesis, biology, and natural history
of CRC.
CRCs arise in the mucosal lining of the large bowel,
which consists of supportive tissue, the lamina propria, and
an epithelial lining that forms multiple crypts (Fig. 1). The
crypt can be considered as the smallest functional unit of
the colorectal mucosa [3, 4]. The mouth or opening of the
crypt is at the luminal surface of the mucosa and the base
of the crypt rests on the muscularis mucosae, a tiny muscle
layer that separates the mucosa from the submucosa.
Epithelial cells lining the crypt are born in the basal part, or
bottom, of the crypt, where cell division occurs, and which
is therefore called the ‘‘proliferative compartment.’’ During
their lifecycle, cells migrate toward the luminal surface of
the crypt and they differentiate while losing their prolif-
erative capacity. At the surface they undergo apoptosis and/
or are extruded into the luminal contents of the bowel.
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Cross talk between the epithelial lining of the crypt and its
environment occurs via the myofibroblasts that form a
crypt sheath. The environment is involved in the balance
between cell renewal, proliferation, migration, differentia-
tion, and death, which occurs in a strictly regulated
homeostasis along the longitudinal axis of the crypt [5].
Adenoma–carcinoma sequence
An increasingly growing genetic instability with consecu-
tive alterations in specific genes, such as oncogenes and
tumor suppressor genes and maintenance and repair genes,
leads ultimately to autonomous and invasive growth, as
observed in cancer. Traditionally, colorectal carcinogenesis
is described with the adenoma–carcinoma sequence; that is,
a stepwise tumor progression model in which consecutive
stages from normal to preinvasive stages ultimately lead to
an invasive carcinoma with the capacity to metastasize
because of the increasing accumulation of genetic
alterations (Fig. 2). The model provides us with the
information needed to investigate the timing of the genetic
aberrations that accumulate and the accompanying status of
cancer-related signaling pathways [6]. It has recently been
made clear that adenoma formation is preceded by a time
interval during which the ground (i.e., the intestinal
mucosa) is fertilized for tumor growth, but without a
manifestation visible to the naked eye [7]. Since the pre-
cursor lesions of the tumors are usually only visible after
the age of 50 years, this implies that much of the time
window suitable for preventive measures and risk assess-
ment lies before this age.
Pretumor progression
It thus takes a long time before a cell accumulates a suf-
ficiently heavy mutational load to turn into a cell that is
able to generate a tumor [8, 9]. Therefore, visible tumor
formation is preceded by a phase called ‘‘pretumor
Fig. 1 The crypt in the colon and the crypt–villus axis in the small
intestine. The crypt is surrounded by a sheath of a single layer of
myofibroblasts and lined with epithelial cells comprising three main
types of cells: enterocyte absorptive cells, goblet cells, and enteroen-
docrine cells. In the small intestine, there is a fourth cell type present
in the bottom of the crypt, the Paneth cell. Together with the two stem
cell populations—crypt base columnar cells and ?4 cells—they form
the crypt base. Above the crypt base, transit-amplifying cells
constitute the progenitor zone
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progression’’ which starts from birth [10]. During a cancer
patient’s life, mutations occur from birth and may remain
for decades without visible changes, followed by
10–15 years of visible adenoma formation eventually
progressing to colorectal carcinoma. The first mutations
that occur at the very beginning of pretumor progression do
not visibly alter the phenotype of the cells in the crypt.
Even patients carrying germline mutations in TP53 or APC
at birth initially have no discernable phenotypes. Never-
theless, these two genes are among the commonest and
most important tumor suppressor genes in solid tumors
such as CRC [11, 12].
It is generally thought that the earliest event during
pretumor progression leading to colorectal carcinogenesis
occurs in the stem cell compartment. Only the stem cells
can live long enough to acquire multiple mutations that are
then fixed into the genome of their progeny and in this
fashion are passed on to following generations. It is pos-
tulated that cancer risk directly relates to the number of
stem cell divisions because the more divisions occur, the
higher the chance for stem cells to gain mutations [13].
Once sufficient mutations have accumulated during the
pretumor progression phase, the stem cells convert to a
recognizable neoplastic cell which initiates the visible
tumor progression phase. For a thorough understanding of
colorectal tumorigenesis, study of stem cell behavior is a
prerequisite.
Stem cells
Stem cells are located in the stem cell niche at the bottom
of the crypt and are responsible for the maintenance of
crypt homeostasis by continuously replenishing the
epithelial crypt lining [14] (Fig. 1). Their identity was first
investigated by Cheng and Leblond [15], who called these
cells, which were interspersed among Paneth cells in the
small bowel, ‘‘crypt base columnar cells.’’ These cells are
defined as a group of undifferentiated cells with the specific
capacity to produce a variety of cell types, including
transit-amplifying cells, which are destined to proliferate
and migrate along the crypt toward the surface while dif-
ferentiating at the cost of their proliferative capacity [16].
The complete life cycle of these cells takes about 5 days,
and the entire epithelial lining of the gut is replaced once a
week [17]. Since stem cells are the only cells capable of
preserving their population as well as producing an off-
spring of differentiated cells that forms the epithelial lining
of the intestinal crypt, their numbers must be maintained
[18].
To describe how stem cells maintain their numbers—
say, by homeostatic self-renewal—two different models
were proposed [19, 20]. In the first model, the deterministic
model, stem cells exist in the stem cell niche and each cell
generates exactly one stem cell and one transit-amplifying
cell by asymmetric division. Transit-amplifying cells con-
tinue to differentiate, and the stem cell in this model is
‘‘immortal,’’ acquiring accumulated mutations as a fast
track to neoplasia, resulting in a fixed number of stem cells.
A more acceptable model that was postulated recently is
the stochastic model. This model proposes that each stem
cell in the stem cell compartment is equally prone to
become extinct over time and by chance yield zero, one, or
two stem cells (corresponding to two, one, or zero transit-
amplifying cells). If zero daughter stem cells are formed,
the specific stem cell clone information is lost and the stem
cell is replaced by the neighboring stem cell, a process
which is called ‘‘neutral drift’’ [21, 22]. In the short term,
the stem cell replacement follows this neutral drift pattern,
leading to neutral competition among all stem cells instead
of a hierarchical organization [23]. According to this
model, new lineages appear randomly, and eventually a
Fig. 2 Adenoma–carcinoma sequence. Enhanced longevity of stem
cells occurs in early stages of pretumor progression and it is
accompanied by increasing genetic instability and accumulation of
mutations. When multiple mutations are acquired, the invisible phase
of pretumor progression ends and visible tumor progression begins.
These preinvasive stages are grossly visible, are morphologically well
defined, and can be recognized as adenomas. LOH loss of
heterozygosity
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single ancestral stem cell lineage is maintained and occu-
pies the entire crypt, which is called ‘‘niche succession’’
[24]. It is estimated that on average every 8 years niche
succession will occur in the normal human colon as a result
of this continuous crypt cell turnover [10, 25].
Stem cells are rapidly dividing cells living stably in the
stem cell niche and continuously transferring their genetic
information to the next generation, in this fashion consti-
tuting the main pool of stem cells. However, under certain
circumstances, such as injury or damage, these fast-cycling
stem cells are replenished by slow-cycling stem cells which
will perform a similar function [26]. This alternative stem
cell pool originates from cell position ?4 when one counts
from the bottom of the crypt and is directly located above
the Paneth cell zone [27, 28]. These two subpopulations of
stem cells were referred to by Cheng and Leblond [29] as
the ‘‘stem cell zone model’’ and by Potten [27] as the ‘‘?4’’
model.
Stem cell microenvironment
Stem cell behavior is also affected by the intestinal stem
cell niche, which provides a microenvironment suitable for
stem cells to live in. In the stem cell niche, myofibroblasts
are the first layer of subepithelial cells around the crypts
which can interact with the stem cells [5, 30]. By either
direct contact or paracrine secretion, myofibroblasts can
modulate stem cell behavior via activation of conserved
signaling pathways such as the Wnt and bone morpho-
genetic protein pathways [5, 31–33]. Paneth cells are also
found to act as key players because of their proximity to the
stem cells [34, 35]. The Paneth cells produce factors such
as epidermal growth factor, transforming growth factor a,
and Wnt3, all essential for activation of the Wnt pathway
and stem cell maintenance [36, 37]. The formation of
organoids from intestinal tissue samples is markedly
improved when Paneth cells are co-cultured with stem
cells, and Gfi1-/- and Sox9-/- mice which have no
apparent Paneth cells contain decreased numbers of
intestinal stem cells [36, 38, 39]. However, Kim et al. [40]
generated a knockout mouse model to deplete the Paneth
cell component. The Lgr5? stem cells still could continu-
ously proliferate, differentiate, and occupy the entire bot-
tom of the crypt without the assistance of Paneth cells.
Complete loss of Paneth cells can be accomplished by
inducible depletion of the transcription factor Math1, and
in this situation, the maintenance and proliferation of stem
cells remained normal [41]. Stem cells alternatively have
an effect on Paneth cells. Depletion of Lgr5? stem cells
will result in the premature death of Paneth cells, further
evidence of their close interrelationship [42]. Research on
the interaction between the niche and stem cells is still in
the very early stages, and more work is needed to clarify
how the crypt microenvironment accommodates stem cells.
Stem cell markers
One problem associated with tracing intestinal stem cells is
that they cannot be easily identified through their mor-
phology. Therefore, much effort has been put into identi-
fication of their specific biomarkers. Currently, it is
generally accepted that leucine-rich repeat containing
G-protein-coupled receptor 5 (LGR5), a G-protein-coupled
receptor, is specifically expressed on the surface of crypt
base columnar cells. LGR5 was found throughout the entire
gastrointestinal tract [43–45]. Culturing of Lgr5? stem
cells will result in the formation of long-lived, self-orga-
nizing crypt–villus organoids [46], and Lgr5? stem cells
are the source of the continual replenishment that maintains
the crypt homeostasis [47]. LGR5 also serves as an
essential mediator for Wnt signal transduction by inter-
acting with R-spondins, and in this way contributes to
maintaining the stemness of stem cells [48, 49]. After
ablation of Lgr5? cells, their function may be compensated
for by cells other than the Lgr5? cells [50]. These cells
turned out to be Bmi1? cells, which are quiescently located
at the ?4 cell position relative to the crypt base, suggesting
that Bmi1? stem cells form a reserve stem cell pool [50].
Thus, these two distinct stem cell populations imply a
model where Lgr5? stem cells mediate homeostatic self-
renewal and Bmi1? stem cells mediate injury-induced
regeneration [26, 50]. Although they are two distinct stem
cell populations, there is nevertheless a bidirectional lin-
eage relationship between active and quiescent stem cell
states which implies they may mark overlapping cell
populations [51–55] Furthermore, about 20 % of Lgr5?
stem cells remain quiescent and express Lgr5 before they
differentiate. If the intestine is injured, they give rise to
differentiating epithelial cells; that is, the function of Lgr5?
stem cells and of Bmi1? stem cells is not completely
mutually exclusive but shows overlap [56].
Expression of LGR5 in the human colorectum is extre-
mely low, and visualization by means of immunohisto-
chemistry is challenging, although it has been reported [57–
59]; in situ hybridization of messenger RNA may therefore
be a more feasible method to detect LGR5 expression [43,
60]. Here we compare the levels of LGR5 and BMI1 protein
and messenger RNA expression by means of immunohisto-
chemistry and in situ respectively (Fig. 3). It is clear that
LGR5 can be detected by in situ hybridization mainly in the
base of the crypt, as expected, whereas immunohistochem-
istry shows mostly nonspecific staining. Compared with
LGR5 expression, BMI1messenger RNA is expressed along
the crypt, and is not restricted to a specific compartment or
844 J Gastroenterol (2016) 51:841–852
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cell position. Also with immunohistochemistry, expression
of BMI1 appears nonspecific. In addition to LGR5 and
BMI1, more and more proteins are postulated as potential
stem cell markers (Table 1).
Stem cell dynamics
The stem cell population itself is not a static entity, and it is
thought that in the intestine the different subpopulations of
stem cells can replace each other, which implies an addi-
tional complexity in many dynamic biologic processes,
such as inflammation, repair, and tumorigenesis. To
understand the role of stem cell behavior in tumor devel-
opment, the human stem cell compartment needs to be
studied. Various methods have been established to describe
the stem cell kinetics and dynamics in quantitative terms to
provide us with tools to study their behavior, location, and
numbers. Recent studies used different approaches, notably
stem cell lineage tracing, methylation pattern diversity, and
mitochondrial DNA mutations.
Stem cell lineage tracing
Stem cell lineage tracing enables one to look at the progeny
of a stem cell. The study of its offspring that forms a new
population will uncover the pattern of the stem cell fate and
record the behavior of stem cells [77]. This method can be
performed by the labeling of stem cells with dyes or
radioactive tracers, transfection or viral transduction of
genetic markers, incorporation of stem cell markers by
genetic recombination, or a recent approach that made use
of multicolor reporters [78]. Whatever the technique used,
the basic idea is to label the specified stem cell and trace its
lineage over time. Therefore, finding the appropriate
markers is the first problem that one has to overcome. They
should be specific, easily detectable, and remain unaltered
and stable in different microenvironments. After binding to
the cells, they should not change the features of these cells,
their progeny, and their neighbors. Further, they must keep
their characteristics and pass them on to all progeny
without transferring them to unrelated cells in their sur-
roundings. These requirements count for the complete life
cycle of the cell and its offspring [78].
The earliest studies of lineage tracing in the intestinal
tract were reported by Cheng and Leblond [15] and
Bjerknes and Cheng [79]. By injecting mice with 3H-thy-
midine-labeled cells, they could trace the fate of different
types of cells. During cell division the labeled DNA will be
incorporated and it can then be visualized by autoradiog-
raphy. After 30 h, a heavily labeled columnar cell popu-
lation appeared in the crypt base around cell position 5 and
above, whereas after 66 h after injection, the labeled cells
had migrated downward to around positions ?1 to ?4.
From these observations it was concluded that the stem
cells lie within the crypt base columnar cell population.
However, this was later disputed by Potten et al. [80, 81],
who found that label-retaining cells after radiation damage
were positioned at the ?4 cell position. They argued that
these must be the stem cells because after crypt home-
ostasis had been established, these label-retaining cells
persisted for around 4 weeks.
The identification of Lgr5? cells as stem cells in the
intestinal tract has led lineage tracing into a new era. By
means of an inducible Lgr5EGFP–IRES–CreERT2 knock-in
mouse model, Barker et al. [43] showed that Lgr5? cells
can give rise to all cell lineages present in the intestine and
are maintained for a long time. Sangiorgi and Capecchi
Fig. 3 a Leucine-rich repeat containing G-protein-coupled receptor 5
(LGR5) and BMI1 staining by means of in situ hybridization (ISH)
and immunohistochemistry (IHC) in the same crypt of the normal
colon mucosa. b The same staining in the small intestine. The red dots
indicate the location of LGR5 messenger RNA obtained with ISH.
For BMI1, the ISH staining is nonspecific. Similarly, IHC gives a
nonspecific staining. Magnification 2009
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[82] applied the same method to find out that Bmi1? stem
cells represent a second subpopulation with a long-term
self-renewal capacity that exists in the intestine. Thereafter,
studies focused on the interrelationship between Lgr5? and
Bmi1? stem cells, demonstrating that rapidly cycling
Lgr5? stem cells can be the source of slow-cycling Bmi1?
stem cells, and vice versa [50, 52], as discussed previously.
By using the same approach, Schuijers et al. [83] identified
a small proportion of Lgr5? stem cells which also
expressed Olfm4, which may be a potential marker for stem
cells. Furthermore, by crossing this Lgr5?–Cre recombi-
nase mouse model with a Ki67RFP knock-in allele mouse,
Basak et al. [84] showed that Lgr5? cells are continuously
in cell cycle and that the cells at the ?4 position leave the
cell cycle. Later Snippert et al. [47] created another
exciting model to trace stem cell lineages. They labeled
Lgr5? stem cells in a mouse model with a multicolor Cre-
reporter system to trace the lineages of different stem cells
simultaneously in one crypt. They showed that Lgr5? cells
could give rise to all other intestinal cell lineages, and over
time each crypt was occupied by only one color, implying
that a single clone had eventually taken over the crypt.
Also in adenomas a widespread expression of Lgr5 was
found, which suggested a potential population of stem cells
[85, 86]. However, contrary to this concept, the first con-
tinuous and marker-independent clonal labeling system
identified fewer functional stem cells in the normal murine
intestine as well as in adenomas, consistent with the notion
that only a small amount of stem cells participate in tumor
formation [87]. The above-mentioned studies were




CD44 CBC cells The CD44-/-/Apcmin/? mice, which lack CD44 expression, showed a significant increase in
apoptotic cell numbers at the crypt base between positions 0 and ?4 [61]
Msi-1 (Musashi-1) CBC cells Msi-1 is expressed in only a few Paneth cells of the adult mouse small intestine crypt as determined
by immunohistochemistry, and the cells are also positive for Ki67 staining, which indicates their
proliferative activity [62]
Olfm4 (Olfactomedin-4) CBC cells Olfm4 was first enriched in human colon examined by microarray analysis and then detected




CBC cells Transgenic expression of ASCL2 induces crypt hyperplasia and loss of it leads to the disappearance




CBC cells Smoc2 was detected in CBC cells in a Smoc2EGFP–IRES–CreERT2 knock-in mouse model. When this
mouse model was crossed with an R26R–LacZ Cre reporter mouse, the typical long-lived SCs
were visualized by lineage tracing [54]
SOX9 CBC cells Sox9 EGFP transgenic mice reveal that Sox9EGFP low level expressing cells are enriched in Lgr5?
cells. Single Sox9EGFP low level expressing SCs can generate organoids and continuously
differentiate [67, 68]. SOX9 was also reported to limit proliferation of label-retaining cells in
mouse small intestine [69]
KLF5 (Kru¨ppel-like
factors)
CBC cells First found highly expressed in epithelial crypt cells and then recognized as a potential SC marker
[70]. Depletion of KLF5 from Lgr5? CBC cells in adult mouse intestine leads first to halting of
the proliferation of CBC cells and transit-amplifying cells, accompanied by an increase in




?4 cells Lineage tracing by intercrossing Lrig1-CreERT2 and R26R-LacZ mice reveals that LRIG1 marks
the relatively quiescent SCs and loss of APC in LRIG1 cells induces multiple adenomas via
regulation of ErbB signaling [72, 73]
mTert (mouse Telomerase
reverse transcriptase)
?4 cells The slowing cycling SCs in the small intestine of mTert-GFP transgenic mice are mTert positive




?4 cells Hopx knock-in mouse models were used to verify the function of mTert as a typical SC marker, and
this population of SCs interconverts with Lgr5? SCs [52]
ID1 (Inhibitor of
Differentiation 1)




?4 cells Lineage tracing experiments reveal that DCLK1 is a specific marker of tumor SCs in the polyps of
Apcmin/? mice [76]
ASCL2 achaete–scute complex like 2, DCLK1 doublecortin-like kinase 1, EGFP enhanced green fluorescent protein, GFP green fluorescent
protein, HPOX homeodomain-only protein X, ID1 inhibitor of differentiation 1, IRES internal ribosome entry site, KLF5 Kru¨ppel-like factor 5,
LRIG1 leucine-rich repeats and immunoglobulin-like domains 1, Msi-1 Musashi 1, Olfm4 olfactomedin 4, mTert mouse telomerase reverse
transcriptase, SC stem cell, SMOC2 SPARC-related modular calcium binding protein 2
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performed in mice, and the method can of course not be
applied to human tissues. Although there are many simi-
larities between mice and humans, there are differences too
[88]. Therefore, other methods were developed to study
stem cell lineages in humans.
Methylation pattern diversity
One approach for visualizing stem cell dynamics in humans
is to analyze the diversity of methylation patterns. Methy-
lation is commonly studied for its influence on gene
expression. However, methylation events also occur at CpG
sites in inactive genes in the tissue of interest. Since the gene
is inactive, methylation is less tightly regulated and occurs
randomly during the replication of DNA strands in the stem
cells, providing an epigenetic signature to the stem cell lin-
eage. The diversity in the location and the number of
methylatedCpGs inmethylation tags in a nonfunctional gene
and the number of methylated CpGs will increase with the
longevity of the stem cell lineage and the number of stem cell
divisions [89]. Thus, the history of a crypt can be recorded by
the study of these methylation patterns as epigenetic signa-
tures [90–92]. Each crypt contains various stem cell lineages
which are constantly changing in a dynamic way [58]. This
method of investigating stem cell lineages by means of the
methylation diversity has been described by Yatabe et al.
[93] and Kim et al. [24].
The longer a stem cell lineage has resided in the niche,
the greater the chance that (epi)genetic changes occur and
therefore the greater the diversity of methylation patterns
that exist. For example, a greater diversity of methylation
patterns was shown in the nonexpressed NKX2-5 gene (also
known as CSX) in the crypts of normal-appearing mucosa
of familial adenomatous polyposis (FAP) patients, who
have a germline mutation in the APC gene that inhibits
Wnt activation, compared with colons of normal controls,
indicating that stem cells were present for a prolonged
period in FAP patients during which they acquired these
methylation events. This increase in methylation diversity
is therefore indicative of the fact that niche succession
occurs less frequently in FAP patients than in controls [94].
A mathematical model showed that the estimated time
between niche succession is 32 years in FAP crypts but
8 years in normal colon crypts [10]. This extended long-
evity of the stem cell lineages in FAP patients explains the
higher risk of colon cancer, indicating that methylation
diversity can be used as an epigenetic molecular clock to
record the history of stem cells. Increased longevity of
stem cell lineages and increased number of stem cell
divisions are therefore associated with a higher risk of the
accumulation of mutations and initiation of colorectal
carcinogenesis. This method of studying stem cell
dynamics by means of determination of methylation pat-
tern diversity is a valuable tool in research and could
eventually be useful in a diagnostic setting to predict the
risk of tumor formation. For now, it is not yet feasible to
apply this technique in routine diagnostics because the
entire procedure is time-consuming and tedious.
Mitochondrial genome
An alternative way of visualizing stem cell dynamics in the
intestine is the study of the mutation rate in the mito-
chondrial genome. Unlike other organelles, mitochondria
contain multiple copies of their own circular genome,
mitochondrial DNA, in the mitochondrial matrix [95].
Induced by environmental DNA-damaging agents, such as
free radicals from the respiratory chain, endogenous
mitochondrial reactive oxygen species, and certain drugs,
somatic mitochondrial DNA mutations occur as a general
phenomenon and are easily accumulated because of the
lack of histone protection and limited DNA repair capa-
bilities [96]. This accumulation is random, and increases
with age [95, 97]. Therefore, the number of mutations in
the mitochondrial genome can be used as a biomarker to
study the dynamics of stem cells. Besides sequencing of the
mitochondrial genome, stem cell lineages with mitochon-
drial DNA mutations can be recognized by visualization of
mitochondrial enzyme activity. The largest mitochondrial
gene, that encoding cytochrome c oxidase (COX), is most
prone to be inactivated by a mutation. Inactivation of the
enzymatic activity of COX can be visualized by dual-color
COX and succinate dehydrogenase enzyme histochemistry
[95]. In this method, enzyme histochemistry is simultane-
ously applied for COX (brown) and succinate dehydroge-
nase (blue), another enzyme of the respiratory tract. Cells
mutated for COX appear blue because of the lack of brown
COX staining, whereas COX wild type cells will appear
brown. Using this method, Gutierrez-Gonzalez et al. [98]
identified some partially mutated small intestinal crypts,
providing evidence that these crypts contain multiple stem
cell lineages [99]. COX-mutated crypts were further found
in clusters throughout the entire colon, where the size of
these clusters, which are called ‘‘patches,’’ increased with
age [100]. Thus, stem cell dynamics can be assessed in situ
with simple enzyme histochemistry.
Stem cell dynamics in pretumor progression
Since stem cells serve as the primary source to carry and
pass on mutations leading to intestinal tumor formation,
visualizing stem cell dynamics is an effective way to study
and monitor tumorigenesis. Understanding the role of stem
J Gastroenterol (2016) 51:841–852 847
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cells in pretumor progression might provide us with an
effective way to investigate and predict the natural history
and risk of tumor occurrence. Hereditary CRC syndromes
with a well-established risk of developing CRC are suit-
able human disease models for application of our research
tools to look at pretumor progression and stem cell
dynamics in comparison with normal controls.
Inherited intestinal tumor syndromes, including FAP,
Peutz-Jeghers syndrome (PJS), juvenile polyposis syn-
drome, Lynch syndrome, and sessile serrated polyposis
contribute between 2 and 5 % of CRC cases [101]. Patients
with these inherited syndromes carry the first genetic
alteration with the accompanying risk from birth, and these
syndromes can therefore be considered as relatively well-
defined pretumor progression models. Germline mutations
leading to hereditary CRC will affect stem cell behavior
and cause an accelerated pretumor progression phase.
Indeed, in FAP and PJS, the longevity of the stem cells,
visualized by study of the diversity of methylation patterns,
appeared considerably increased in the normal-looking
intestinal mucosa, compared with healthy controls [102].
Increased longevity is accompanied by an increased pre-
disposition for accumulated additional mutations and sub-
sequent tumor progression [94].
Stem cells in FAP models
FAP is a syndrome caused by a germline mutation of the
‘‘gatekeeper’’ tumor suppressor gene APC (which encodes
adenomatous polyposis coli), where one inherited defective
APC allele leads to progressively growing intestinal neo-
plasia [45]. In its classic form it is characterized by numerous
adenomatous polyps in the colorectum and individuals with
FAP have a virtually 100 % lifetime risk of developing CRC
when no prophylactic surgical removal of the large bowel is
performed [103, 104]. Haploinsufficiency of APC due to a
germline mutation in FAP is associated with crypts that
display increased crypt fission and an increased number of
stem cells [3, 105]. Baker et al. [106] showed that the number
of stem cells further increased in APC-/- crypts compared
with APC?/- crypts. Furthermore, the loss and replacement
rate of the APC-/- stem cells is enhanced, and this accel-
erated division rate ultimately results in the accumulation of
mutations leading to the cancer-prone state. That haploin-
sufficiency of APC leads to the above-mentioned manifes-
tations may be explained by the observation that APC
influences the mitotic spindle orientation and thereby the
balance between asymmetric and symmetric stem cell divi-
sions [107–109].
APC also acts as a key factor in the Wnt signaling
pathway, essential to maintain the physiological home-
ostasis of the stem cell niche [110]. In a complex with axin
and glycogen synthase kinase 3b, APC forms the key
destruction complex of the Wnt signaling pathway through
phosphorylation and subsequent degradation of b-catenin
[111]. Mutational inactivation of APC results in the accu-
mulation of b-catenin in the cytoplasm and translocation to
the nucleus, where it forms a complex with TCF1 that acts
as a transcription factor that activates the Wnt target genes
ultimately leading to tumorigenesis [112]. APC is therefore
an inhibitor of Wnt signaling and APC mutations lead to
aberrant Wnt activation and stimulation of stemness in the
stem cell niche [113, 114]. The self-renewal capacity of
embryonic stem cells can be enhanced by modulation of
APC dose-dependent Wnt signaling [115]. Dow et al. [116]
found that restoration of APC-regulated normal Wnt sig-
naling can cause tumor cells to revert to functional normal
cells. These facts lend support to the use of FAP as a model
for studying stem cells during pretumor progression.
Stem cells in PJS models
PJS is another inherited polyposis syndrome, caused by a
germline mutation in the STK11 gene (also known as LKB1),
with an increased cancer risk, both intraintestinal and
extraintestinal, and it is typically accompanied by mucocu-
taneous skin pigmentations [117, 118]. A mutated STK11
gene leads to loss of polarity of differentiated epithelial cells
[119–121] and a deficiency in p53-mediated intestinal
epithelial cell apoptosis [122]. Mouse models carrying one
mutated STK11 allele are prone to polyp and tumor forma-
tion [123, 124]. When stem cell dynamics in PJS patients
compared with normal controls were analyzed with use of a
methylation assay of the inactive NKX2-5 gene in the
intestinal mucosa, an increased methylation diversity was
found. This indicates that niche succession is prolonged and
mutations can more easily accumulate in the stem cells of
PJS patients [102]. The progenitor zone was also expanded,
consistent with an altered balance between division and
differentiation in the epithelial lining of the intestine in PJS
patients. This misbalance between cell division and differ-
entiation may result in polyp and tumor growth [125]. The
precise mechanism of tumorigenesis due to deficiency of
serine/threonine kinase 11 (encoded by STK11) is still puz-
zling, but it appears that there is a link between serine/thre-
onine kinase 11 and stem cell behavior in the gut. Similarly, a
link seems to exist between serine/threonine kinase 11 and
the hematopoietic stem cell population [126, 127].
Conclusion
Identification of pretumor progression by means of visu-
alization of stem cell dynamics seems to be an effective
way to assess cancer risk. However, the invisible pheno-
type of pretumor progression makes this challenging. On
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the basis of the adenoma-carcinoma sequence, accumulat-
ing mutations during pretumor progression contribute to
tumor formation. These mutations are acquired and
expanded in cells that need to live long enough to build up
a mutational burden. This makes stem cells an attractive
study object since they are considered the primary popu-
lation where tumorigenesis is initiated. Because of the
important role stem cells play in pretumor and tumor
progression, it is essential for researchers to focus on
tracing the dynamics of these stem cells. Although there
are several techniques to visualize this, as summarized in
this review, they all provide indirect evidence, are labor-
intensive and tedious, and are therefore mostly applied in
model organisms [128, 129]. Some approaches allow
studies in the human intestinal mucosa, and these will, in
conjunction with the animal and in vitro studies, ultimately
increase our understanding of the stem cell dynamics in
pretumor progression and provide valuable information for
risk assessment and prevention of intestinal tumorigenesis.
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